Diaceutics (LON:DXRX) Given Buy Rating at Canaccord Genuity Group

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity Group in a research report issued on Tuesday, Digital Look reports. They presently have a GBX 215 price objective on the stock. Canaccord Genuity Group‘s price objective would suggest a potential upside of 8.75% from the company’s current price.

Diaceutics Price Performance

DXRX stock opened at GBX 197.70 on Tuesday. The stock’s 50 day moving average is GBX 185.71 and its two-hundred day moving average is GBX 160.55. Diaceutics has a 52-week low of GBX 125 and a 52-week high of GBX 210. The company has a market capitalization of £167.99 million, a PE ratio of -617.81 and a beta of 0.88. The company has a quick ratio of 9.92, a current ratio of 2.55 and a debt-to-equity ratio of 5.40.

Diaceutics (LON:DXRX) last released its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. Analysts predict that Diaceutics will post 1.01 earnings per share for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.